Eli Lilly and Co. (NYSE:LLY) – Equities research analysts at Jefferies Group upped their FY2017 earnings estimates for shares of Eli Lilly and in a research note issued to investors on Thursday. Jefferies Group analyst J. Holford now forecasts that the brokerage will earn $4.26 per share for the year, up from their previous forecast of $4.12. Jefferies Group has a “Buy” rating and a $105.00 price objective on the stock. Jefferies Group also issued estimates for Eli Lilly and’s FY2018 earnings at $4.49 EPS and FY2020 earnings at $7.10 EPS.

Other research analysts have also issued research reports about the company. Citigroup Inc. restated a “buy” rating on shares of Eli Lilly and in a research report on Wednesday, August 3rd. Argus lifted their target price on Eli Lilly and from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, August 2nd. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 target price on the stock in a research note on Friday, July 29th. BMO Capital Markets reaffirmed a “buy” rating and set a $94.00 target price on shares of Eli Lilly and in a research note on Wednesday, July 27th. Finally, Credit Suisse Group AG reaffirmed a “buy” rating and set a $91.00 target price on shares of Eli Lilly and in a research note on Wednesday, July 6th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $97.06.

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Shares of Eli Lilly and (NYSE:LLY) opened at 79.27 on Monday. The company’s 50 day moving average price is $79.73 and its 200-day moving average price is $77.79. Eli Lilly and has a 1-year low of $67.88 and a 1-year high of $88.16. The firm has a market cap of $83.84 billion, a price-to-earnings ratio of 34.17 and a beta of 0.17.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 EPS for the quarter, meeting analysts’ consensus estimates of $0.86. The business had revenue of $5.40 billion for the quarter, compared to analyst estimates of $5.14 billion. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.90 earnings per share.

In other Eli Lilly and news, insider Donald A. Zakrowski sold 1,213 shares of the business’s stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $83.16, for a total value of $100,873.08. Following the completion of the sale, the insider now owns 1,300 shares of the company’s stock, valued at $108,108. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jackson P. Tai purchased 2,560 shares of Eli Lilly and stock in a transaction on Friday, August 12th. The stock was bought at an average cost of $80.42 per share, with a total value of $205,875.20. Following the transaction, the director now directly owns 42,110 shares of the company’s stock, valued at $3,386,486.20. The disclosure for this purchase can be found here. 0.20% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the company. Iowa State Bank bought a new stake in shares of Eli Lilly and during the second quarter worth $104,000. PineBridge Investments L.P. boosted its stake in shares of Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock worth $108,000 after buying an additional 920 shares in the last quarter. Cribstone Capital Management LLC bought a new stake in shares of Eli Lilly and during the second quarter worth $117,000. Coconut Grove Bank boosted its stake in shares of Eli Lilly and by 3.3% in the second quarter. Coconut Grove Bank now owns 1,550 shares of the company’s stock worth $122,000 after buying an additional 50 shares in the last quarter. Finally, Physicians Financial Services Inc. boosted its stake in shares of Eli Lilly and by 11.2% in the second quarter. Physicians Financial Services Inc. now owns 1,638 shares of the company’s stock worth $129,000 after buying an additional 165 shares in the last quarter. 74.99% of the stock is owned by institutional investors.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.